Breast cancer biotech Syndax Pharmaceuticals refiles for an $86 million IPO
04 January 2016
Syndax Pharmaceuticals, a late-stage biotech developing a novel therapy for treatment-resistant breast cancer, refiled on Monday with the SEC to raise up to $86 million in an initial public offering.
Marinus Pharmaceuticals Completes Enrollment in Phase 3 Trial For Ganaxolone Anti-Seizure Treatment
18 December 2015
Marinus Pharmaceuticals (NASDAQ:MRNS), which focuses on the development of treatments for epilepsy and neuropsychiatric disorders, said it has completed patient recruitment for the Phase 3 clinical trial of ganaxolone, a CNS-selective GABAA modulator, in adults with drug-resistant focal onset seizures.
NovaMedica to invest $15 million in new R&D centre
18 December 2015
The Russian pharmaceutical company, NovaMedica, has announced plans to build a new research and development centre at Technopolis Moscow. The new site will include laboratories with brand new state-of-the-art equipment and will allow the company to run up to fifteen projects each year and means that they will be able to produce approximately 75 million doses per year thanks to the production areas.
NovaMedica Will Invest $15 mln in Technological Centre Construction in Technopolis Moscow
16 December 2015
The Russian pharmaceutical company NovaMedica that is a Rusnano portfolio company will start technological centre construction in Technopolis Moscow to develop and produce on a pilot basis innovative medical products.
Clearside closes $20M round for candidates that are injected into the eye's suprachoroidal space
09 December 2015
Ophthalmology company Clearside Biomedical just announced a $20 million Series C financing round to develop its proprietary formulation of triamcinolone acetonide that's delivered into the eye's suprachoroidal space via a microinjector, which it says is 10 times shorter than those used to administer drugs into the middle of the eye.
Pocket or Flap Delivery of Corneal Inlays: Does it Really Matter?
02 December 2015
With the emergence of corneal inlays for the correction of presbyopia, there has been debate on how to implant these devices into the cornea. Of the four inlays on the market, the manufacturers of three of them recommend implanting intrastromally—in a corneal pocket—and one is designed for implantation under a flap.
26 November 2015
Epigenetics deals with the study of gene expression without altering the gene sequence. The epigenetic change associated with gene expression happens with the modification of the transcription mechanism. The key components that are involved in the regulation of epigenetic transcription are DNA methylation, micro RNA, histone modifications, and non-coding RNA’s.
3-year-old pharma looks set to fight rectal and eye problems, and then 15 more
21 October 2015
NovaMedica, a young Russian pharma, has been increasingly focused on nanotechnology in its R&D. For example, in the most recent development, this U.S.-Russian JV is about to start a series of clinical trials for its new drug candidate to treat the dangerous inconveniences of hemorrhoids. This is the firm’s inaugural product based on in-house R&D results without tapping into external technologies, the project owners said, claiming that “the drug candidate is built on a unique action mechanism untapped in products currently available in the market.”
Diagnostics Special Report: Non-invasion of the body snatchers
15 October 2015
Despite the rapid advances in identifying and understanding the nature of driver mutations and resistance markers in various cancers—information that is going a long way to individualizing patient care—the challenge of fully characterizing a cancer within a single patient remains significant. Even in situations where a solid tumor exists, it is not always possible to obtain a tissue biopsy due to clinical inaccessibility or unacceptable risks to patient safety.
EyewireTV — Raindrop Near Vision Inlay PMA; MillennialEYE Live
06 October 2015
In this week's EyewireTV, ReVision Optics submits to the FDA the fourth and final module of the company’s premarket approval application for the Raindrop near vision inlay; and Ocular Therapeutix submits a new drug application to the FDA for Dextenza (dexamethasone 0.4 mg) for the treatment of ocular pain following ophthalmic surgery. Also, future and current leaders in ophthalmology discuss the hottest topics from annual MillennialEYE Live meeting in Hollywood.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024